Advisory Alpha LLC Raises Stake in Boston Scientific Corporation $BSX

Advisory Alpha LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 14.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 6,859 shares of the medical equipment provider’s stock after purchasing an additional 860 shares during the period. Advisory Alpha LLC’s holdings in Boston Scientific were worth $737,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. SYM FINANCIAL Corp purchased a new position in Boston Scientific during the 2nd quarter worth $202,000. Wealth Watch Advisors INC purchased a new position in Boston Scientific during the 2nd quarter worth $186,000. Teacher Retirement System of Texas lifted its stake in shares of Boston Scientific by 6.9% in the 2nd quarter. Teacher Retirement System of Texas now owns 931,793 shares of the medical equipment provider’s stock worth $100,084,000 after acquiring an additional 60,144 shares during the period. Transcend Capital Advisors LLC lifted its stake in shares of Boston Scientific by 30.3% in the 2nd quarter. Transcend Capital Advisors LLC now owns 11,347 shares of the medical equipment provider’s stock worth $1,219,000 after acquiring an additional 2,638 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after acquiring an additional 2,899,653 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 1.4%

Shares of NYSE BSX opened at $101.00 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The firm has a 50-day moving average price of $101.07 and a 200 day moving average price of $102.22. The stock has a market capitalization of $149.66 billion, a price-to-earnings ratio of 54.01, a price-to-earnings-growth ratio of 2.06 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the business earned $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Morgan Stanley raised their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. BTIG Research restated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Robert W. Baird raised their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $123.77.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total transaction of $296,598.24. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at $2,467,460.16. This trade represents a 10.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 180,204 shares of company stock worth $18,544,846 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.